Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

Interest in the human gut microbiome and the influence it exerts on a person’s wellbeing, from cognitive health to immunity, has been rapidly increasing in recent years.

In this episode of HBW Insight's Over the Counter podcast, we speak to Dublin-based food company Kerry Group about a particularly exciting, emerging area of microbiome-based wellness, postbiotics, which are defined by the International Scientific Association of Probiotics and Prebiotics (ISAPP) as a “preparation of inanimate microorganisms and/or their components that confers a health benefit on the host.”

Given that postbiotics rely on inanimate ingredients, rather than live cultures as in yoghurts, they may provide more suitable vehicles for consumer health innovation, suggests Kerry Group’s RDA senior manager of immune and joint health, Sonja Nodland.

Nodland also explains what kinds of postbiotics are currently on the European market, for example for digestive and skin health and immunity, and the regulatory challenges that postbiotics share with other microbiome products in the region, such as pre- and pro-biotics.

Open Media

Timestamps

2:20 Introductions

4:00 What are postbiotics?

8:30 Advantages of postbiotics for consumer health innovation

10:20 Health benefits of postbiotics

12:00 Types of postbiotics

15:20 Kerry’s postbiotic portfolio

19:00 Postbiotic regulation in the European Union

28:00 Where to start with postbiotic innovation

Guest Bio

Sonja Nodland, PhD is Senior RDA Manager for Immune and Joint Health at Kerry. She conducted her graduate studies at Washington University in St. Louis and the University of Minnesota studying both molecular mechanisms of microbial pathogenesis and cancer and human immunology. After finishing her postdoctoral research at the University of Minnesota in basic human developmental immunology she joined a pharmaceutical startup company to combine her scientific interests in immunology and the health effects of microbial products on the human immune system. Her current scientific interests are related to the relationship of microbiome health to human immune health and the pleiotropic effects of microbial-derived products on human general health.

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Europe

EU JCA: Milestone Report Shows Room For Improvement For Orphan Drugs And PICOs

In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By 

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

Marinomed Starts Restructuring Proceedings As Debts Mount

 
• By 

Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.

Perrigo Adds High-Strength Paracetamol To UK Solpadeine Line

 
• By 

Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative. 

More from Geography

Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

 

Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By 

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By 

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.